In 2019, the phase 3 ADMIRAL trial demonstrated the efficiency of gilteritinib monotherapy for patients with FLT3-mutated R/R AML, significantly prolonging overall survival (OS) compared with four standard salvage chemotherapy regimens (median OS 9.3 vs. 5.6 m, HR 0.64, P < 0.001) (11). This evidence concerns the gene FLT3 and acute myeloid leukemia.